April 19, 2014

Popular Weight Loss Drug Could Cause Permanent Liver and Kidney Damage

xenical Popular Weight Loss Drug Could Cause Permanent Liver and Kidney Damage

By Dr. Mercola

The weight loss drug orlistat (known as Xenical by prescription and Alli, available over-the-counter) is one of the most popular on the market.

Alli is even known to flaunt the fact that it’s approved by the U.S. Food and Drug Administration (FDA) in its advertisements, using such slogans as “lose weight the FDA approved way,” which, to most people, makes it sound as though it’s safe…

The drug, which works by inhibiting fat absorption in your intestines, has faced problems in the past, not the least of which include cramping, gas, diarrhea, anal leakage and oily underwear stains as the result of the drug’s fat-blocking mechanism of action.

Now, a University of Rhode Island researcher uncovered a far more detrimental side effect, which is so severe it prompted him to immediately alert the FDA about his findings…

Xenical and Alli May Cause “Severe Toxicity of Internal Organs”

Orlistat was first approved in 1999 as a prescription weight loss drug, and later, in 2007, became approved for over-the-counter use. Because orlistat works in your intestines, it was thought that the drug mostly stayed in the intestines and was not absorbed by the body. This was not what was found by Professor Bingfang Yan, who conducted the study.

He noted:1

“Since it has been available over–the-counter, there has been a drastic increase of toxicity among patients using the drug. It has been linked to severe liver failure, acute pancreatic failure and acute renal (kidney) failure.”

His research, indeed, showed that orlistat, even at low levels, inhibits a major detoxification enzyme (carboxylesterase-2) in the liver, kidney and gastrointestinal track. When this occurs, it may lead to “severe toxicity of internal organs such as the liver and kidney.” The enzyme also plays a role in metabolizing a variety of medications, and as such orlistat may also alter the efficacy of certain drugs. In particular, the study found orlistat may:

  • Reduce the effectiveness of certain cancer drugs; cancer cells actually multiplied faster when orlistat was taken2
  • Amplify the anti-clotting effects of aspirin, which may increase your risk of internal and external bleeding

In 2010, the FDA required Xenical and Alli to include a warning on their labels about cases of severe liver injury that had been reported with the use of the drugs, although at the time it called the side effects “rare.”3

Weight Loss Drugs Have a Troubled Past

Obesity carries with it serious health risks, including cancer, heart disease and type 2 diabetes, and with rates increasing steadily it is a condition that needs to be taken seriously. However, potentially risking your life with dangerous weight loss drugs is a risk that is just too steep to take.

The serious side effects tied to Xenical and Alli are only the latest to emerge. In 2010, the weight loss drug Meridia (sibutramine) was taken off the market after studies showed it increased the risk of heart attack and stroke. The saddest part about the story is that Meridia showed signs of dangerous side effects ever since it was first approved in 1997, but was only taken off the market more than a decade later, after millions of people had already taken the drug.

In fact, when Meridia was approved it carried a warning on its label stating that the drug should not be used in people with a history of heart disease, heart failure, heart-rhythm problems or stroke. The drug, which worked by suppressing your appetite by altering levels of the brain chemicals serotonin and norepinephrine, was also widely known to raise blood pressure and heart rate, and an FDA advisory panel actually recommended against its approval in 1996 for this very reason.

Public Citizen later petitioned the FDA to ban the drug in 2002, alleging that it was responsible for causing dozens of deaths and hundreds of adverse patient reactions since it came to market. In 2005, the FDA again considered placing stricter warnings on the drug, and in January 2010 finally asked Abbott, the drug’s maker, to strengthen the warning following review of preliminary data from the SCOUT study.4

The SCOUT study, which ultimately led the FDA to request the drug be removed from the market entirely, found a 28 percent increased risk of heart attack and a 36 percent increased risk of stroke in patients taking Meridia compared to placebo.

Those are steep risks for a drug that only lead to an average weight loss of 9.5 pounds a year — hardly worth risking a fatal heart attack or stroke over. And this is quite typical for weight loss drugs, which generally only amount to a weight loss of anywhere from four to 22 pounds… 5

Why is the FDA Speeding Approval of More Weight Loss Drugs?

Despite the known risks of liver damage, and other health effects, from weight loss drugs already on the market, the FDA is moving full speed ahead to approve new options. In fiscal year 2012, the FDA approved 35 new drugs, the same number as were approved in fiscal year 2011, which they said was “among the highest number of approvals in the past decade, surpassed only by 2009 (37).”6,7 This included two new weight loss drugs – the first to hit the market since 2009:

Qsymia

A combination of two FDA-approved drugs, phentermine  (the “phen” of diet drug fen-phen, which was pulled from the market in 1997 after it was linked to serious heart valve damage) and topiramate, an anti-seizure epilepsy drug. After one year of treatment with the recommended and highest daily dose of the drug, patients had an average weight loss of 6.7 percent and 8.9 percent, respectively. Along with an increased risk of birth defects (such that women must have a negative pregnancy test prior to starting on the drug), Qsymia can increase heart rate and must not be used in patients with glaucoma or hyperthyroidism.

According to the FDA:8

“…This drug’s effect on heart rate in patients at high risk for heart attack or stroke is not known. Therefore, the use of Qsymia in patients with recent (within the last six months) or unstable heart disease or stroke is not recommended. Regular monitoring of heart rate is recommended for all patients taking Qsymia, especially when starting Qsymia or increasing the dose.”

Belviq

Belviq works by activating the serotonin 2C receptor in your brain, which may help you eat less or feel full after eating smaller amounts of food. Fen-Phen’s damaging effect on the heart valve was thought to be related to activation of the serotonin 2B receptor on heart tissue, and while the FDA notes that Belviq “does not appear to activate the 2B receptor” when used at the approved dose, they are already aware of serious side effects.

The FDA stated:9

Belviq should not be used during pregnancy. Treatment with Belviq may cause serious side effects, including serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors. These include, but are not limited to, drugs commonly used to treat depression and migraine. Belviq may also cause disturbances in attention or memory.

…  Because preliminary data suggest that the number of serotonin 2B receptors may be increased in patients with congestive heart failure, Belviq should be used with caution in patients with this condition. Belviq has not been studied in patients with serious valvular heart disease. The drug’s manufacturer will be required to conduct six postmarketing studies, including a long-term cardiovascular outcomes trial to assess the effect of Belviq on the risk for major adverse cardiac events such as heart attack and stroke.”

In other words, although the drug is already approved, it still has to undergo extensive testing to make sure cardiovascular problems can be ruled out… and as for the weight loss “benefit,” patients lost, on average, just 3 percent to 3.7 percent of their body weight after one year. While regular echocardiograms were not recommended by the FDA for people taking Belviq, Dr. Eric Felner, who was a member of the FDA advisory panel that approved the drug, told Slate.com that in his opinion:10

“If you’re going to put your patient on this medication, you need to see them somewhere along the lines of every two to three months and probably get an echocardiogram at least two or three times a year.”

Tips for Losing Weight Naturally: More Fat, Fewer Carbs…

Switching from a carb-based diet to a fat- and protein-based diet will help rebalance your body’s chemistry, and a natural side effect of this is weight loss, and/or improved weight management once you’re at an ideal weight. One explanation for this is that you don’t really get fat from eating too much and exercising too little. Nor do you get fat from eating fat.

It is also vital to select healthy fats. Avoid virtually all vegetable oils that are loaded with omega-6 fats. Fried foods are also taboo. You will want to replace the lost carb calories with healthy fats like coconut oil, olives, olive oil, avocados, eggs, butter and high-fat nuts like macadamia nuts.

One researcher that has clearly established this is Dr. Richard Johnson, whose latest book, The Fat Switch, dispels many of the most pervasive myths relating to diet and obesity.

Dr. Johnson discovered the method that animals use to gain fat prior to times of food scarcity, which turned out to be a powerful adaptive benefit. His research showed that fructose activates a key enzyme, fructokinase, which in turn activates another enzyme that causes cells to accumulate fat. When this enzyme is blocked, fat cannot be stored in the cell. Interestingly, this is the exact same “switch” animals use to fatten up in the fall and to burn fat during the winter.

Fructose is the dietary ingredient that turns on this “switch,” causing cells to accumulate fat, both in animals and in humans.

In essence, overeating and excess weight could be viewed as a symptom of an improper diet. It’s not necessarily the result of eating too many calories, per se, but rather getting your calories from the wrong sources. In the blossoming new field of nutrigenomics, the study of how nutrients interact with your genes, food contains information, as well as nutrients and calories. That information can turn on or off the expression of certain genes, epigenetically, as it were. In simple terms, when you consume too many sugars and carbs, you set off a cascade of chemical and epigenetic reactions in your body that reprograms your level of hunger and craving for sweets:

  • First, fructose is metabolized differently from glucose, with the majority being turned directly intofat because fructose stimulates a powerful gene-mediated “fat switch.”
  • This rapidly leads to weight gain and abdominal obesity (“beer belly”), decreased HDL, increased LDL, elevated triglycerides, elevated blood sugar, and high blood pressure — i.e., classic metabolic syndrome.
  • Dietary carbohydrates, especially fructose, are also the primary source of a substance called glycerol-3-phosphate (g-3-p), which causes fat to become fixed in fat tissue
  • At the same time, high carb intake raises your insulin levels, which prevents fat from being released
  • Fructose further tricks your body into gaining weight by turning off your body’s appetite-control system. Fructose does not suppress ghrelin (the “hunger hormone”) and doesn’t stimulate leptin (the “satiety hormone”), which together result in feeling hungry all the time, even though you’ve eaten. As a result, you overeat and develop insulin resistance, which is not only an underlying factor of type 2 diabetes, heart disease, and a long list of other chronic diseases

The resulting equation is simple: fructose and dietary carbohydrates (grains, which break down into sugar) lead to excess body fat, obesity and related health issues. Furthermore, no amount of exercise can compensate for this damage because if you eat excessive “carbs,” i.e. fructose and grains — the primary ingredients NOT found in our ancestral diet — it will activate programming to cause your body to become, and remain, fat.

A reasonable goal will be to have as much as 50-70 percent of your diet as healthy fat, which will radically reduce your carbohydrate intake. It can be helpful to remember that fat is far more satiating than carbs, so if you have cut down on carbs and feel ravenous, this is a sign that you have not replaced them with sufficient amounts of healthy fat. Sources of healthy fats that you’ll want to add to your diet include:

  • Olives and Olive oil (for cold dishes)
  • Coconuts, and coconut oil (for all types of cooking and baking)
  • Butter made from raw grass-fed organic milk
  • Raw Nuts, such as, almonds or pecans
  • Organic pastured egg yolks
  • Avocados
  • Pasture finished meats
  • Palm oil
  • Unheated organic nut oils

Most people will likely notice massive improvement in their health by following this approach, as they are presently consuming FAR more grain and bean carbohydrates in their diet, and any reduction will be a step in the right direction. To help you get started on the right track, review my Nutrition Plan, which guides you through these dietary changes one step at a time.

Read the full article here: http://articles.mercola.com/sites/articles/archive/2012/12/26/weight-loss-drug-orlistat.aspx


0 commentsback to post

Other articlesgo to homepage

U.S Congressman: CDC Can’t be Trusted Regarding Vaccine Safety

U.S Congressman: CDC Can’t be Trusted Regarding Vaccine Safety

Congressman Bill Posey’s strong resolve and demands for transparency were evident as he discussed the Center for Disease Control (CDC)’s handling of vaccine safety studies which affect “our most precious resource in our nation – our children.” The 30-minute interview, conducted by vaccine industry watchdog, PhD biochemist Brian Hooker, delves into what Posey called “the incestuous relationship between the public health community and the vaccine makers and public officials.”

The Florida legislator, known as “Mr. Accountabililty,” did not mince words when criticizing current and past CDC officials including indicted fraudster Dr. Poul Thorsen; CDC director turned Merck Vaccine President Dr. Julie Gerberding; and the agency’s current spokesperson regarding autism and vaccines, Dr. Coleen Boyle.

Congressman Posey said, “The CDC can’t be trusted regarding investigating vaccine safety. Huge conflict of interest. I think the CDC should be investigated.”

Merck’s Former Doctor Predicts that Gardasil will Become the Greatest Medical Scandal of All Time

Merck’s Former Doctor Predicts that Gardasil will Become the Greatest Medical Scandal of All Time

In an interview with Dr. Bernard Dalbergue, a former pharmaceutical industry physician with Gardasil manufacturer Merck, he predicts that Gardasil will become the greatest medical scandal of all time. Dr. Dalbergue believes that at some point in time, the evidence will add up to prove that this vaccine, technical and scientific feat that it may be, has absolutely no effect on cervical cancer and that all the very many adverse effects which destroy lives and even kill young girls, serves no other purpose than to generate profit for the manufacturers.

Deadly Medicines and Organized Crime: How big pharma has corrupted healthcare

Deadly Medicines and Organized Crime: How big pharma has corrupted healthcare

An important new book by a recognized medical research expert describes Big Pharma as akin to the Mafia. In an interview conducted by our colleagues at ANH-Europe, Dr. Peter C. Gøtzsche exposes the flaws of the drug approval system, our reliance on dangerous drugs, and the deadly co-dependence between regulators and industry. Dr. Gøtzsche is co-founder of the highly respected Cochrane Collaboration and Cochrane Reviews, a leading journal of evidence-based medicine. The interview is particularly timely now that the FDA has decided to remove restrictions on the dangerous drug Avandia.

Dr. Gøtzsche’s new book, Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare, points out that the pharmaceutical industry is allowed to test their own drugs, and thus effectively be their own judge. He calls this a threat to safe medicine and asks for open access to all research data, including raw data, because otherwise, data can be easily suppressed and conclusions manipulated by industry.

Medical Cannabis is a Threat to the Pharmaceutical Industry

Medical Cannabis is a Threat to the Pharmaceutical Industry

Medical marijuana, or cannabis, is legal in 20 US states, where it is used for a variety of medical conditions such as mood disorders, pain disorders, multiple sclerosis, and even cancer. Parents of children with epilepsy met at a news conference to share their dismay that Governor Mark Dayton refuses to legalize medical marijuana. About 85 percent to 95 percent of Americans are in favor of medical cannabis, and nearly 60 percent are in favor of legalizing marijuana. Cannabis shows outstanding promise as a medicinal plant, largely due to its cannabidiol (CBD) content. Cannabinoids interact with your body by way of naturally occurring cannabinoid receptors embedded in cell membranes throughout your body.

Leaders of Teaching Hospitals Have Close Ties to Drug Companies, Study Shows

Leaders of Teaching Hospitals Have Close Ties to Drug Companies, Study Shows

Pharmaceutical company payments to doctors extend far beyond rank-and-file clinicians — and deep into the leadership of America’s teaching hospitals, according to a study published recently in the Journal of the American Medical Association.

A team of researchers at the University of Pittsburgh Medical Center examined the boards of the 50 largest drug companies by global sales (excluding three companies that were not publicly traded). The researchers found that 40 percent — 19 companies — had at least one board member who also held a leadership role at an academic medical center. Sixteen of the 17 companies based in the United States had at least one. Several had more than one. All told, the research team found that 41 of the companies’ 2012 board members held leadership positions at academic medical centers. Six of the 41 were pharmaceutical company executives who served on hospital boards of directors or held other leadership posts.

The authors wrote that when academic medical leaders serve on pharmaceutical company boards, it can lead to conflicts not only for individuals, but for the critically important health care institutions they guide.

read more


Get the news right in your inbox!